Analysts’ Recent Ratings Changes for Apogee Therapeutics (APGE)

Posted by Xavier Holt on Dec 18th, 2024

Apogee Therapeutics (NASDAQ: APGE) has recently received a number of price target changes and ratings updates:

12/12/2024 – Apogee Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim.
12/3/2024 – Apogee Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $110.00 price target on the stock, up previously from $95.00.
12/2/2024 – Apogee Therapeutics had its price target raised by analysts at Wedbush from $87.00 to $90.00. They now have an “outperform” rating on the stock.
11/27/2024 – Apogee Therapeutics had its price target raised by analysts at Guggenheim from $95.00 to $110.00. They now have a “buy” rating on the stock.
11/25/2024 – Apogee Therapeutics is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $89.00 price target on the stock.
11/25/2024 – Apogee Therapeutics is now covered by analysts at Canaccord Genuity Group Inc.. They set a “buy” rating and a $89.00 price target on the stock.
11/12/2024 – Apogee Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.
10/25/2024 – Apogee Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.

Apogee Therapeutics Stock Performance

APGE opened at $48.09 on Wednesday. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -19.87 and a beta of 2.30. Apogee Therapeutics, Inc. has a fifty-two week low of $22.20 and a fifty-two week high of $72.29. The company has a fifty day moving average of $51.11 and a 200 day moving average of $48.32.

Insider Buying and Selling

In other Apogee Therapeutics news, Director Mark C. Mckenna purchased 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $49.54 per share, with a total value of $990,800.00. Following the completion of the purchase, the director now directly owns 20,000 shares in the company, valued at $990,800. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $48.76, for a total transaction of $221,370.40. Following the completion of the transaction, the insider now directly owns 258,073 shares of the company’s stock, valued at $12,583,639.48. The trade was a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 94,535 shares of company stock worth $5,133,635. Corporate insiders own 36.10% of the company’s stock.

Institutional Trading of Apogee Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Arizona State Retirement System raised its stake in shares of Apogee Therapeutics by 4.5% in the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock valued at $236,000 after acquiring an additional 258 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in Apogee Therapeutics by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock valued at $94,000 after purchasing an additional 285 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Apogee Therapeutics in the 3rd quarter worth about $71,000. Principal Financial Group Inc. lifted its stake in Apogee Therapeutics by 26.3% in the second quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after purchasing an additional 1,340 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its position in shares of Apogee Therapeutics by 25.7% during the third quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company’s stock valued at $517,000 after buying an additional 1,800 shares during the period. 79.04% of the stock is currently owned by institutional investors.

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.